Journal of Nuclear Cardiology is the official publication of the American Society of Nuclear Cardiology. It is a peer-reviewed journal that publishes original research articles and discussions about the current and future role of nuclear cardiology and other imaging modalities. The journal is the only one in the world devoted to this dynamic and growing subspecialty.
One of the key metrics used to evaluate the quality of a journal is its impact factor. This is a measure of the average number of citations received per article in a particular journal over a specific period. The impact factor of a journal is an important indicator of its reputation and influence in the field. The Journal of Nuclear Cardiology has an impact factor of 2.4 as of 2022, which is a testament to its high quality and relevance in the field of nuclear cardiology.
The impact factor of the Journal of Nuclear Cardiology is a reflection of the quality of the research published in the journal and its relevance to the field of nuclear cardiology. It is an important metric that is used by researchers, clinicians, and other stakeholders to evaluate the impact and influence of the journal. The impact factor of the journal is expected to continue to grow in the coming years, as more researchers and clinicians recognize the value of the research published in the journal.
Key Takeaways
- Journal of Nuclear Cardiology is the only journal in the world devoted to nuclear cardiology.
- The impact factor of Journal of Nuclear Cardiology is 2.4 as of 2022, reflecting its high quality and relevance in the field.
- The impact factor of the journal is expected to continue to grow in the coming years, as more researchers and clinicians recognize the value of the research published in the journal.
Journal Overview
The Journal of Nuclear Cardiology (JNC) is a peer-reviewed medical journal that is published by Springer. The ISSN for the journal is 1071-3581. JNC is indexed in the Science Citation Index Expanded (SCIE), which is a part of the Web of Science. The journal is also indexed in other databases such as Embase, Scopus, and PubMed.
Scope and Aim
JNC is the official publication of the American Society of Nuclear Cardiology. The journal focuses on the use of nuclear imaging techniques in the diagnosis and treatment of cardiovascular diseases. The scope of the journal includes original research articles, review articles, case reports, and editorials. JNC also covers topics related to the current and future role of nuclear cardiology and other imaging modalities.
Editorial Board
The editor-in-chief of JNC is Marcelo Di Carli, who is a professor of radiology at Harvard Medical School and the director of nuclear medicine and molecular imaging at Brigham and Women’s Hospital. The editorial board of JNC consists of experts in the field of nuclear cardiology from around the world. The board members are responsible for reviewing and selecting manuscripts for publication in the journal.
JNC is committed to publishing high-quality research that is relevant to the field of nuclear cardiology. The journal provides a platform for researchers and clinicians to share their findings and ideas with the wider scientific community. However, readers should note that the information provided in JNC is not a substitute for professional medical advice. Readers should always consult their healthcare provider before making any decisions about their health.
Impact Factor Analysis
Calculation Method
The impact factor (IF) of the Journal of Nuclear Cardiology is a measure of the average number of citations received per paper published in the journal during the previous two years. It is calculated by dividing the number of citations in the current year to articles published in the previous two years by the total number of articles published in the previous two years. The IF is widely used as a metric to evaluate the quality and importance of a journal.
The IF of the Journal of Nuclear Cardiology has been calculated by both Journal Citation Reports (JCR) and Scopus. According to the JCR, the 2022 IF of the journal is 3.383, which is an increase from the 2021 IF of 2.812. The 2022 IF places the journal at rank 28 out of 135 journals in the Cardiac and Cardiovascular Systems category, and rank 40 out of 143 journals in the Radiology, Nuclear Medicine and Medical Imaging category.
Historical Impact Factor Trends
Over the past five years, the IF of the Journal of Nuclear Cardiology has shown an upward trend. In 2018, the IF was 2.530, which increased to 2.812 in 2021. The 2022 IF of 3.383 represents a significant increase from the previous year. The journal’s IF has consistently placed it in the top quartile of journals in the Cardiac and Cardiovascular Systems category.
According to Scimago Journal & Country Rank, the journal’s SJR (SCImago Journal Rank) for 2022 is 0.609. The SJR is a measure of the scientific influence of scholarly journals that accounts for both the number of citations received by a journal and the importance or prestige of the journals where the citations come from.
It is important to note that the IF is just one metric used to evaluate the quality and impact of a journal. Other factors, such as the number of downloads and citations outside of the two-year window used to calculate the IF, should also be taken into consideration when evaluating a journal’s impact.
Disclaimer: The information provided is based on the available data at the time of writing and may be subject to change. The IF should be used as a tool to evaluate a journal’s impact, but should not be the sole factor considered when making decisions about where to publish or what journals to read.
Publication and Access
The Journal of Nuclear Cardiology (JNC) is a peer-reviewed scientific journal that is published by the American Society of Nuclear Cardiology (ASNC). The journal is devoted to the subspecialty of nuclear cardiology and other imaging modalities. As of January 1, 2024, Elsevier began publishing the JNC.
Copyright and Licensing
For all open access content, the Creative Commons licensing terms apply. The journal’s copyright policy is clearly stated on its homepage, and authors are required to sign a copyright agreement before publication. The journal provides authors with the option to retain copyright for their articles, subject to certain conditions.
Access Options
Access to the JNC is available through a subscription, which is a complimentary benefit of ASNC membership. The journal is also available through Springer, which provides access to the journal’s content online. Springer offers a variety of access options, including individual subscriptions, institutional subscriptions, and online access to back issues.
Overall, the JNC is a reputable journal with a high impact factor. It provides authors with the option to retain copyright for their articles, and offers a variety of access options to readers. However, it is important to note that access to the journal may be restricted to those who do not have a subscription or ASNC membership.
Clinical Significance and Research
Nuclear cardiology has been instrumental in the diagnosis and management of cardiac amyloidosis. Cardiac amyloidosis is a rare but serious condition that can lead to heart failure. The use of nuclear imaging techniques has greatly improved the diagnosis of this condition, allowing for earlier intervention and improved outcomes.
Cardiac Amyloidosis Research
Research in nuclear cardiology has also led to significant advancements in the diagnosis and treatment of cardiac amyloidosis. The use of nuclear imaging techniques has allowed for the development of new diagnostic criteria and guidelines for the management of this condition. This has led to earlier diagnosis and improved outcomes for patients.
Technological Advancements in Nuclear Cardiology
Technological advancements in nuclear cardiology have also greatly improved the accuracy and efficiency of cardiac imaging. These advancements include the use of artificial intelligence (AI) training and text and data mining to improve the accuracy of diagnoses. Data mining techniques have also allowed for the identification of new biomarkers and the development of new imaging protocols.
The development of new technologies has also led to the development of new radiopharmaceuticals, which have greatly improved the accuracy and specificity of nuclear imaging. These advancements have allowed for earlier diagnosis and treatment of cardiac conditions, leading to improved outcomes for patients.
In conclusion, nuclear cardiology has had a significant impact on the diagnosis and management of cardiac conditions, particularly cardiac amyloidosis. The development of new technologies and research in this field has greatly improved the accuracy and efficiency of cardiac imaging, leading to earlier diagnosis and improved outcomes for patients. However, it is important to note that further research is needed to fully understand the clinical significance of these advancements and to develop new guidelines for the management of cardiac conditions.
Frequently Asked Questions
What is the current impact factor of the Journal of Nuclear Cardiology?
The current impact factor of the Journal of Nuclear Cardiology is 2.4, as of 2022. The impact factor is a measure of a journal’s importance and is calculated by the number of citations received by articles published in the journal over a two-year period divided by the total number of articles published in that same period.
How has the impact factor for the Journal of Nuclear Cardiology evolved over recent years?
The impact factor for the Journal of Nuclear Cardiology has remained consistent over recent years. In 2022, the impact factor was 2.4, which was the same as the previous year. The 5-year impact factor, which takes into account citations over a longer period, has also remained steady at 2.4.
Who constitutes the editorial board of the Journal of Nuclear Cardiology?
The editorial board of the Journal of Nuclear Cardiology consists of a team of experts in the field of nuclear cardiology and related imaging modalities. The board is responsible for reviewing and selecting articles for publication, ensuring the quality and accuracy of the content, and guiding the direction of the journal. The current editorial board is composed of renowned experts in the field, including Ami E. Iskandrian, Panithaya Chareonthaitawee, Timothy M. Bateman, and Mouaz H. Al-Mallah.
Which publisher is responsible for the distribution of the Journal of Nuclear Cardiology?
The Journal of Nuclear Cardiology is published by Springer, a leading global publisher of scientific, technical, and medical literature. Springer is responsible for the distribution of the journal, both in print and online.
What abbreviation is commonly used for the Journal of Nuclear Cardiology in academic citations?
The abbreviation commonly used for the Journal of Nuclear Cardiology in academic citations is J Nucl Cardiol. This abbreviation should be used in all references to the journal in academic writing.
What are the guidelines for authors wishing to publish in the Journal of Nuclear Cardiology?
The Journal of Nuclear Cardiology welcomes original research articles, clinical observations, and reviews of nuclear cardiology subjects and related fields. All articles submitted for publication must be original and not under consideration for publication elsewhere. The journal follows strict ethical guidelines for publication, and authors are required to declare any conflicts of interest. Detailed guidelines for authors can be found on the journal’s website.